Chronic myeloid leukemia (CML) is a type of leukemia—a cancer of the bone marrow and blood.
Better Survival Rates for CML
Studies have shown that the first treatment you receive for cancer is by far the most important. On average, leukemia patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere. Our patients diagnosed with CML receive expertly targeted, comprehensive care from a team of specialists who focus almost exclusively on treating this disease.
Access to Clinical Studies
SCCA, with its founding organizations Fred Hutch and UW Medicine, is a world leader in leukemia research and was formed, in part, to bring promising new treatments to patients faster. For people with CML, this means more treatment options than you might find elsewhere, including the chance to participate in a clinical study for CML.
Our researchers pioneered one of the most effective leukemia treatments, bone marrow transplantation, more than 50 years ago and continue to refine it today—for example, developing transplant options for people who have not found a matched donor. We are also advancing other key leukemia treatments, including testing new drugs and cancer vaccines as well as new combinations of treatments.
A Leader in Bone Marrow Transplant
Targeted therapies are the standard treatment for CML. With these therapies chronic-phase disease can be managed for many years, perhaps indefinitely. For people whose disease progresses or does not respond to standard treatment, bone marrow transplant may be an option.
If your condition requires a bone marrow transplant, you should know that the Fred Hutch Bone Marrow Transplant Program at SCCA is one of 15 centers whose patients achieved higher-than-expected survival rates, according to a multi-year study by the Center for International Blood and Marrow Transplant Research. We’ve performed more bone marrow transplants than any other institution in the world.